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Abstract
Key pathological features of Parkinson’s Disease (PD) include the progressive degeneration of mid-
brain dopaminergic (DA) neurons and hindbrain noradrenergic (NA) neurons. The loss of DA
neurons has been extensively studied and is the main cause of motor dysfunction. Importantly,
however, there are a range of ‘non-movement’ related features of PD including cognitive dysfunc-
tion, sleep disturbances and mood disorders. The origins for these non-motor symptoms are less
clear, but a possible substrate for cognitive decline may be reduced adult-hippocampal neurogene-
sis, which is reported to be impaired in PD. The mechanisms underlying reduced neurogenesis in
PD are not well established. Here we tested the hypothesis that NA and DA depletion, as occurs
in PD, impairs hippocampal neurogenesis. We used 6-hydroxydopamine or the immunotoxin
dopamine-b-hydroxylase-saporin to selectively lesion DA or NA neurons, respectively, in adult
Sprague Dawley rats and assessed hippocampal neurogenesis through phenotyping of cells birth-
dated using 5-bromo-20-deoxyuridine. The results showed no difference in proliferation or differ-
entiation of newborn cells in the subgranular zone of the dentate gyrus after NA or DA lesions.
This suggests that impairment of hippocampal neurogenesis in PD likely results from mechanisms
independent of, or in addition to degeneration of DA and NA neurons.
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1 | INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disease that mostly
affects individuals over 60 years old. The pathology of PD is generally
described as a degeneration of dopamine (DA) neurons of the substan-
tia nigra pars compacta (SNpc), which leads to motor impairments that
include rigidity, tremor, and bradykinesia (Samii, Nutt, & Ransom,
2004). However, PD is a multisystem disorder, and the progressive
pathology also impacts various other nuclei including the locus cœru-
leus (LC; Halliday, 2012; Zweig, Cardillo, Cohen, Giere, & Hedreen,
1993), basal forebrain (Hall et al., 2014; Nakano & Hirano, 1984), olfac-
tory structures (Pearce, Hawkes, & Daniel 1995) and the raphe nuclei
(Halliday, Blumbergs, Cotton, Blessing, & Geffen, 1990).
While often described as a motor disease, PD patients also exhibit
a wide range of non-motor symptoms, including olfactory impairment,
depression, and mild cognitive impairments progressing to dementia in
late-stage disease (Barbosa, 2013). Thus, exploring the relationship
between nonmotor symptoms and patterns of pathology in specific
brain regions is becoming an increasingly important area in PD
research.
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Hippocampal neurogenesis has been linked to cognitive function
and is reportedly reduced in parallel with the onset of age-related cog-
nitive decline (Small, Schobel, Buxton, Witter, & Barnes, 2012). Further-
more, hippocampal neurogenesis has been suggested to be deficient in
PD patients, with MRI studies showing that PD patients with dementia
have smaller hippocampi than patients without dementia (Camicioli
et al., 2003; Laakso et al., 1996). H€oglinger et al. (2004) also investi-
gated hippocampal neurogenesis levels in PD patients, reporting fewer
numbers of neuronal precursors.
Since the reports correlating impaired hippocampal neurogenesis
to nonmotor symptoms in PD patients, a number of studies have
focused on identifying factors responsible for regulating hippocampal
neurogenesis in order to identify therapeutic targets (Geraerts, Krylysh-
kina, Debyser, & Baekelandt, 2007; Kotani, Yamauchi, Teramoto, &
Ogura, 2008; Malberg, Eisch, Nestler, & Duman, 2000; Meneghini
et al., 2014; Vaidya, Vadodaria, & Jha, 2007). DA degeneration has
been suggested to be a key factor underlying a decrease in neurogene-
sis in the hippocampus (H€oglinger et al., 2004; Park & Enikolopov,
2010; Suzuki et al., 2010). Indeed, Suzuki et al. (2010) used 6-
hydroxydopamine (6-OHDA) to remove midbrain DA neurons and
observed a reduction of proliferating cells in the subgranular zone
(SGZ) of the dentate gyrus (DG), a finding also reported in a study using
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (H€oglinger et al.,
2004). However, the specificity of both 6-OHDA and MPTP are not
limited to DA. 6-OHDA targets all catecholamines (Breese & Traylor,
1970) and MPTP also affects noradrenaline (NA) and serotonin (5HT)
neurons (Gupta, Felten, & Gash, 1984; Namura et al., 1987). Conse-
quently, it is possible that NA depletion was underestimated in these
previous studies, and may play an important role in the reduced hippo-
campal neurogenesis reported.
Supporting this hypothesis, we recently demonstrated that the DG,
which receives a dense innervation from NA neurons originating in the
LC, completely lacks innervation from midbrain DA neurons (Ermine,
Wright, Parish, Stanic, & Thompson, 2016). Furthermore, reports that
NA neuronal degeneration may precede DA neuronal degeneration in
PD (Braak & Del Tredici, 2008), combined with nonmotor symptoms
that arise prior to motor dysfunction (Tolosa, Compta, & Gaig 2007),
provides correlative support for the hypothesis that NA plays a role in
regulating cell proliferation and neurogenesis in the SGZ. To test this,
we compared the effect of DA depletion and NA depletion alone, or
together, on cell proliferation and neurogenesis in the SGZ of adult rats.
2 | MATERIALS AND METHODS
2.1 | Animals
Adult female Sprague Dawley (SD) rats were used in this study. All pro-
cedures were conducted in accordance with the Australian National
Health and Medical Research Council’s published Code of Practice for
the Use of Animals in Research, and experiments were approved by the
Florey Institute of Neuroscience and Mental Health Animal Ethics Com-
mittee. All animals were group housed in individually ventilated cages
under a 12 hr light/dark cycle with ad libitum access to food and water.
2.2 | Surgical procedures
The rats were anesthetised with isoflurane (5% at 1 L/min) and main-
tained under anaesthesia for the duration of the surgery (2%, 1 L/min).
The animals were placed in a stereotaxic frame (Kopf, Germany) and a
small burr-hole was drilled in the skull to administer the following toxins
at a rate of 1 mL/min: (1) 14 mg of 6-OHDA [Tocris, in 0.02% ascorbic
acid (Sigma) and saline (0.9% NaCl)] into the medial forebrain bundle
(MFB) (4.2 mm anterior and 1.2 mm lateral to bregma, 7.8 mm below
dura) with i.p. injection of desipramine (20 mg/kg) 30 min prior to surgery
to protect NA neurons; (2) 1 mg of dopamine-b-hydroxylase saporin
(DBH-saporin) in the intra cerebral ventricle (i.c.v.; 0.6 mm anterior and
1.5 mm lateral to bregma, 3 mm below dura); (3) both 6-OHDA (14 mg in
MFB) and DBH-saporin (1 mg in i.c.v.); (4) saline in MFB and/or i.c.v.
Animals were sacrificed at either four or nine weeks postlesion to
confirm selective neuronal (DA and/or NA) ablation and assess the
impact of the treatments on SGZ cell proliferation. The four-week
time-point was chosen for its relevance to study designs in the existing
literature (Baker, Baker, & Hagg, 2004; H€oglinger et al., 2004; Suzuki
et al., 2010). The nine-week time-point allowed a sufficient time for
the newborn cells to differentiate into their neuronal phenotype and
investigates a longer-term effect of the lesions on neurogenesis.
2.3 | Lesion validation by assessing DA
and NA levels using HPLC
To validate the DA and NA lesions, we assessed DA and NA levels in
the brain four weeks after lesioning using high performance liquid
chromatography (HPLC). DA and NA levels were assessed at the level
of terminal fields in the striatum or hippocampus, as described previ-
ously in detail (Parish et al., 2001). In brief, animals were decapitated
and the striatum and hippocampi were rapidly dissected, weighed, and
snap-frozen for storage at 280 8C until analysis, at which point sam-
ples were homogenised in an extraction buffer containing 0.4M
perchloric acid, 7.9 mM sodium metabisulphite, 1.34 mM disodium
ethylenediaminetetra-acetic acid (EDTA) in distilled water. To rupture
vesicular membranes, samples were sonicated for 15 s and centrifuged
at 10,000g (3 3 5 min). The resultant supernatant was transferred to
HPLC vials and placed in an autosampler for injection onto the HPLC.
The HPLC consisted of a LC-20AT pump (Shimadzu), SIL-20A Auto-
sampler (Shimadzu), and C18 reverse phase column (Bio-Rad, Hercu-
les, USA). Detection was via a 3 mm VT-03 flow cell with glassy
carbon working electrode (Antec Leyden) and Decade II Electrochemi-
cal Detector (Antec Leyden). The mobile phase consisted of 17% v/v
methanol in purified deionized water containing 70 mM KH2PO4
(Merck), 0.5 mM EDTA (Merck), and 8.0 mM sulfonic acid (Merck), pH
3.0 and was run at a flow rate of 0.5 mL/min.
2.4 | 5-Bromo-20-deoxyuridine (BrdU) treatment
Four weeks postsurgery, 56 rats across the different treatment groups
were injected with BrdU (50 mg/kg, i.p.) every 12 hr for seven days to
label dividing cells over a one week period.
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2.5 | Tissue collection and immunohistochemistry
Animals were sacrificed by a terminal dose of pentobarbitone (100 mg/kg;
Virbac, Peakhurst, Australia) and transcardially perfused with paraformal-
dehyde media (PFA, 4% in 0.4M phosphate buffer with 0.2% picric acid).
Brains were collected and further postfixed for 2 hr in PFA, followed by
cryo-protection in 20% sucrose PBS solution for 1–2 days. After freezing
the brains on dry ice, 40 mm-thick coronal sections were collected in 1:12-
series using a freezing-microtome (Leica, Wetzlar, Germany).
Free-floating immunohistochemistry for tyrosine hydroxylase (TH),
DBH, BrdU, Ki67, and Prox1 were performed on a 1:12 or 1:6 series as
previously described (Thompson, 2005). Tissues used for BrdU labelling
were pretreated by incubation in Omnipur deionized formamide (Merck
Millipore) at 65 8C for 2 hr, in 2M HCL at 37 8C for 30 min and in Borate
buffer at room temperature for 20 min. Primary antibodies and dilutions
used were: sheep anti-BrdU (Exalpha, A205P, 1:1000); mouse anti-DBH
(Millipore, MAB308, 1:5000); rabbit anti-TH (Pel-freeze, P40101-0,
1:1000); rabbit anti-Ki67 (Thermo Fisher, LBVRM-9106-S1, 1:1000); rab-
bit anti-prox1 (Millipore, ABN278, 1:2000). Secondary antibodies and
dilution factors were: antirabbit and antisheep conjugated to Dylight Flu-
orophores 488 and 549 (Jackson ImmunoResearch, 1:200) for fluorescent
staining and antimouse, antirabbit, antigoat, and antisheep conjugated to
biotin (Jackson ImmunoResearch,1:400) for chromogenic staining.
2.6 | Analysis
Fluorescent microscopic analysis and images were performed using a
Zeiss Meta confocal microscope (LSM 780) and chromogenic images
were captured using a Leica DM6000 microscope.
The number of BrdU1 and Ki671 cells in the SGZ were quantified
across six sections located at2.6, 2.84, 3.08, 3.32, 3.56, and 3.8 mm cau-
dal to bregma. The number of BrdU/Prox1 double positive cells was also
quantified, by random selection of 80 BrdU1 cells located in the SGZ
across three to six sections (ranging from 2.6 to 3.8 mm caudal to bregma)
and analysis of double-labelling through orthogonal reconstruction using
the confocal microscope, to identify them as Prox1 positive or negative.
Statistical analysis was performed using a Kruskal-Wallis with
Dunn’s multiple comparison test to assess the difference of DA and
NA levels at their terminal fields between the lesioned and saline con-
trol groups. The difference among the groups in BrdU1 cells, Ki671
cells, and BrdU1/Prox11 double positive cells in the DG was assessed
via one-way ANOVA, with a Dunnett’s multiple comparison test. The
difference between the groups in the number of BrdU1 cells and
Ki671 cells in the SVZ was assessed via an unpaired t-test.
3 | RESULTS
3.1 | Unilateral ablation of midbrain DA neurons
or hindbrain NA neurons results in a robust reduction
of each neurotransmitter in the respective striatal
or hippocampal terminal fields
To test whether the DA system and/or the NA system are involved in
regulating adult hippocampal neurogenesis, we performed three
different lesions: (1) selective ablation of NA neurons in the LC using
the toxin DBH-saporin; (2) selective ablation of DA neurons from the
SNpc/ventral tegmental area (VTA) using 6-OHDA and desipramine;
and (3) double lesions of DA and NA neurons from the SNpc and LC,
respectively, using 6-OHDA and DBH-saporin. Four weeks post-lesion,
BrdU was administered i.p. twice daily for seven days. Animals were
perfused at either four weeks after lesioning, to verify success of the
lesions, or nine weeks after lesioning, to assess the impact on cell-
proliferation and neurogenesis (Figure 1a).
HPLC was performed four weeks after toxin injection to allow for
initial validation of both lesions and to give a quantitative measure of
the impact of the lesions on NA and DA transmitter levels in the termi-
nal fields (Figure 1b,c). Administration of DBH-saporin resulted in a 13-
fold reduction of NA levels in the hippocampus compared with the
control group (NA lesion: mean6 SEM50.229060.036 nM/mg of
tissue, n58; control: mean6SEM52.99860.2475 nM/mg of tissue,
n515; p5 .0006; DA lesion: mean6 SEM53.26860.15 nM/mg of
tissue, n58, Figure 1b), but did not affect the level of striatal DA (Fig-
ure 1c). The 6-OHDA1 desipramine lesion resulted in an 8.8-fold
reduction in striatal DA compared with controls (DA lesion: mean6
SEM553.76621.88 nM/mg of tissue, n58; control: mean6
SEM5218.866.621 nM/mg of tissue, n516; p5 .0008; NA lesion:
mean6 SEM5249621.78 nM/mg of tissue, n58, Figure 1c) but did
not affect the level of hippocampal NA (Figure 1b).
Immunohistochemical identification of NA and DA neurons and
fibres nine weeks after toxin injection, allowed for final validation of both
the NA and DA lesions. In animals injected with DBH-saporin the num-
ber of NA cell bodies in the LC and corresponding fibres in the hippocam-
pus were markedly reduced compared with saline injected controls
(Figure 1d–g). Similarly, animals that received 6-OHDA1desipramine
treatment showed a significant loss of TH immunoreactivity in the SNpc
and striatum, (Figure 1h–k). Thus, robust DA and NA lesions were vali-
dated both at neuroanatomical and biochemical levels.
3.2 | Unilateral removal of either the DA or NA
projection systems does not affect hippocampal cell
proliferation or neurogenesis
To determine the number of adult-born cells in the SGZ and their phe-
notypic fate, we pulsed adult rats with BrdU for a period of seven days
beginning four weeks after lesioning, and performed histological analy-
sis after a further four week period - nine weeks post-lesion. We
observed no difference in the number of BrdU1 cells in the SGZ
between all treatment groups (saline control group: mean6
SEM5182616.96, n515; NA lesion: mean6 SEM5178.5618.44,
n58; DA lesion: mean6 SEM5177.4618.0, n58; double lesion:
mean6 SEM5181.3624.96, n57; p5 .9979; Figure 2a–e).
Because the number of BrdU1 cells at nine weeks postlesion
reflects the survival of cells generated during the seven-day pulse
period, we also quantified the number of actively dividing Ki671 cells
in the SGZ as a more specific measure of proliferation. Lesioning of the
DA or NA systems alone, or in combination, did not significantly affect
the number of Ki671 cells in the SGZ quantified across six sections
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FIGURE 1 DBH-saporin and 6-OHDA successfully lesion the NA and DA systems, respectively, in adult SD rats. Lesioned animals were
killed at 4 weeks for confirmation of selective lesioning, or killed at 9 weeks (after 7 days of bi-daily BrdU injections at 4 weeks), to assess
hippocampal neurogenesis (a). As confirmed by HPLC 4 weeks after toxin administration, NA lesions induced a 13-fold reduction in NA lev-
els in the hippocampus (b) and DA lesions induced a 9-fold reduction of DA levels in the striatum (c), compared with their respective control
groups. Immunohistochemical detection of DBH using a brightfield microscope in controls (d) and lesioned animals (e), reveals a reduction in
the number of NA cell bodies in the LC 9 weeks after DBH-saporin administration. Darkfield imaging of chromogenically labelled DBH in
the hippocampus shows the intact NA system in control animals (f), compared with an almost complete ablation of NA fibres in lesioned ani-
mals (g). The analysis of TH immunoreactivity 9 weeks after 6-OHDA administration showed an almost complete ablation of DA cell bodies
in the right SNpc (h vs. i) and axon terminals in the striatum (j vs. k). Statistical analysis: Kruskal-Wallis with Dunn’s multiple comparison
test, *** p .0006 (b) and *** p5 .0008 (c), error bars5 Standard deviation. For control groups n516, for lesion groups n58. Scale bars: d,
e,h,i,j,k5500 mm and f,g5200 mm. Abbreviations: DBH, dopamine-b-hydroxylase; TH, tyrosine hydroxylase; NA, noradrenaline; DA, dopa-
mine; LC, locus cœruleus; HPLC, high performance liquid chromatography; SD, Sprague Dawley; SNpc, substantia nigra pars compacta [Color
figure can be viewed at wileyonlinelibrary.com]
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spanning the temporal hippocampus (control: mean6 SEM557.536
4.80, n515; NA lesion: mean6 SEM558.38610.512, n58; DA
lesion: mean6 SEM565.6365.558, n58; double lesion: mean6
SEM566.25616.0, n58; p5 .8468; Figure 2f–j).
To assess the effect of NA or DA loss on the differentiation of
new-born cells in each group, the proportion of BrdU1 cells that
adopted a Prox11 phenotype (broadly expressed in granular neurons
of the SGZ) was quantified. Four weeks after BrdU administration, the
percentage of BrdU1 cells to adopt a Prox11 identity in the SGZ was
not significantly different from control numbers in any of the treatment
groups (control: mean6SEM576.34%61.92, n515; NA lesion:
mean6 SEM579.53%61.89, n58; DA lesion: mean6 SEM5
75.54%62.82, n57; double lesion: mean6 SEM578.57%62.43,
n57; p5 .6016; Figure 3a–e).
FIGURE 2 The number of surviving new-born and proliferative cells in the SGZ of adult rats is unchanged 9 weeks following DA or NA
lesions, or combined double lesions. Immunohistochemistry for BrdU in representative sections from the control (a), NA lesion (b), DA lesion
(c), and the double lesion DA & NA group (d) 4 weeks after the last BrdU injection. Quantification in the SGZ across 6 sections did not
reveal any difference in BrdU1 numbers between the control and experimental groups (e). Immunohistochemistry for Ki67 in representative
sections from the control (f), NA lesion (g), DA lesion (h), and double lesion groups (i) 9 weeks after the initial lesioning. Quantification in
the SGZ across 6 sections did not reveal any difference in Ki671 numbers between the control and experimental groups (j). Statistical anal-
ysis: (e,j) One-way ANOVA with Dunnett’s test for multiple comparison, F3,3450.013 and p5 .9979 (e), F3,3550.2696 and p5 .8468 (j).
Error bars5Standard deviation. For control groups n516, for lesion groups n58. Scale bars: a–d and f–i 100 mm. Abbreviations: BrdU, 5-
bromo-20-deoxyuridine; NA, noradrenaline; DA, dopamine; SGZ, subgranular zone
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3.3 | Depletion of striatal DA with 6-OHDA does not
affect the number of BrdU1 cells or proliferating
Ki671 cells in the SVZ
While a recent study found fewer proliferating cells in the SGZ after mid-
brain DA neuron lesions in adult rats (Suzuki et al., 2010), reduced prolifer-
ation in the SVZ has been more widely reported following DA deficiency
(Baker et al., 2004; H€oglinger et al., 2004; Winner et al., 2006). We aimed
to confirm these reports of reduced SVZ proliferation in our experimental
setting, to obtain an ‘internal control’ from which to contextualize the neg-
ative findings from our analysis of the hippocampus. We therefore quanti-
fied the number of BrdU1 and Ki671 cells in the SVZ across three
coronal sections from animals nine weeks after lesioning (four weeks after
the one-week BrdU pulse period) and compared the DA lesion and control
groups. Given the almost complete absence of NA innervation of the stria-
tum and SVZ, the NA lesion group was not assessed.
In contrast to previous reports, we found that depletion of striatal
DA by lesioning SNpc neurons with 6-OHDA, did not affect SVZ cell
turnover based on the number of BrdU1 cells labelled over seven
days, four to five weeks after 6-OHDA lesioning (Figure 4a–c) (control:
mean6 SEM5808630.98, n58; DA lesion: mean6 SEM5808.36
49.88, n58; p5 .9968) or Ki671 cells nine weeks after lesioning (Fig-
ure 4d–f) (control: mean6 SEM514306120.8, n58; DA lesion:
mean6 SEM51513691.54, n58; p5 .5926).
3.4 | Cell proliferation in the SGZ and the SVZ is not
transiently affected acutely after DA and NA lesions
In the context of the existing literature, we were surprised at the lack
of impact that DA lesions had on the number of adult-born surviving
BrdU1 cells and actively proliferating Ki671 cells in the SGZ, and par-
ticularly the SVZ. While we were originally focused on evidence for sta-
ble and potentially long-term changes, we considered we may have
missed a more transient reduction in cell turnover after lesioning. To
test this, NA or DA ablation was performed in a new cohort of animals,
and sacrificed four weeks post-lesion (Figure 5a) to assess cell-
proliferation based on immunohistochemistry for Ki67. The extent of
lesioning at four weeks was similar to the DA or NA neuronal cell loss
seen at the nine-week post-lesion time-point, including a robust reduc-
tion of DBH1 cell bodies in the LC and associated fibres in the hippo-
campus in DBH-saporin-treated animals (Figure 5b–e), and similarly
robust loss of midbrain DA neurons and associated striatal projections
following 6-OHDA treatment (Figure 5f–i).
The effect of lesioning on SGZ and SVZ cell proliferation was
assessed by comparing the number of Ki671 cells in the NA-lesion,
DA-lesion and control groups (Figure 5j,k). In the SGZ, no difference in
the number of Ki671 cells was found when comparing NA and DA
lesions with control (Control: mean6 SEM5100610.38, n58; NA
lesion: mean6 SEM5112.4615.22, n57; DA lesion: mean6
SEM5114.9620.15, n58; p5 .7726). Similarly, there was no signifi-
cant impact of DA lesions on the number of Ki671 cells in the SVZ
(Control: mean6 SEM515986121.2, n57; DA lesion: mean6
SEM51673682.25, n57; p5 .6199).
4 | DISCUSSION
These results of DA and/or NA denervation having no effect on cell
proliferation and neurogenesis suggest that hippocampal neurogenesis
is not directly regulated by the DA or NA systems in the adult rat brain,
FIGURE 3 Neurogenesis in the SGZ of adult rats is unchanged at 9 weeks following DA or NA lesions, or combined double lesions. A
representative image from a control animal showing immunohistochemistry for BrdU and Prox1 at 4 weeks after the 7-day BrdU pulse
period that was used to quantify the number of neurons generated in that time (a–d). (b–d) represents a high magnification example of a
BrdU1/Prox11 cell. A total of 80 BrdU1 cells in the dentate SGZ were assessed for Prox1 immunoreactivity by orthogonal reconstruction
of confocal images in order to determine the fractional contribution to BrdU1 cells (e). Statistical analysis: (e) One-way ANOVA with Dun-
nett’s test for multiple comparison, F3,3250.6291 and p5 .6016. Error bars5 Standard deviation. For control groups n516, for lesion
groups n58. Scale bars: A 200 mm. Abbreviations: BrdU, 5-bromo-20-deoxyuridine; NA, noradrenaline; DA, dopamine; SGZ, subgranular
zone [Color figure can be viewed at wileyonlinelibrary.com]
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and thus is unlikely to directly underlie a link between loss of these
neurons and cognitive decline in PD. This is consistent at a neuroana-
tomical level with our recent report on the lack of direct innervation of
the hippocampus from midbrain DA neurons (Ermine et al., 2016). At a
functional level however, the results contrast to previous studies,
where DA has been described as a regulator of adult hippocampal neu-
rogenesis (Broussard, 2012; H€oglinger et al., 2004; Mu, Zhao, & Gage,
2011; Suzuki et al., 2010; Wisman, Sahin, Maingay, Leanza, & Kirik,
2008).
The existing literature is notably mixed with respect to conclusions
that DA either positively or negatively regulates hippocampal neuro-
genesis. For example, in MPTP-induced rodent models of PD, low
doses of MPTP reportedly decrease proliferation (H€oglinger et al.,
2004) while higher doses increase proliferation (Park & Enikolopov,
2010). Further confusion comes from pharmacological replacement
studies, where the D2 antagonist haloperidol has been reported as
having no effect (Malberg et al., 2000), decreasing (Wakade, Mahadik,
Waller, & Chiu, 2002) or increasing (Keilhoff, Grecksch, & Becker,
2010) SGZ proliferation levels. Haloperidol has also been reported to
have no effect on (Halim, Weickert, McClintock, Weinberger, & Lipska,
2004), and to increase (Keilhoff, Grecksch, Bernstein, Roskoden, &
Becker, 2010) survival of adult-born cells in the DG.
The hippocampus receives a dense innervation from the locus
coeruleus NA system (Loughlin, Foote, & Bloom, 1986; Loy, Koziell,
FIGURE 4 Adult-born and proliferating cells in the SVZ remain unchanged after 6-OHDA-induced striatal DA lesions in adult rats. Repre-
sentative examples of BrdU immunoreactivity in the SVZ of control (a) and DA lesion groups (b). Cell counts showed no difference in the
number of BrdU1 cells generated 4–5 weeks after lesioning (c). Representative examples of Ki67 immunoreactivity in the SVZ of control (d)
and DA lesion groups (e). Cell counts showed no difference in the number of Ki671 cells detected 9 weeks after lesioning (f). Statistical
analysis: (c,f) unpaired t-test, p5 .9968 (c) p5 .5926 (f). Error bars5 Standard deviation. For all groups n58. Scale bars: a–e, 200 mm.
Abbreviations: BrdU, 5-bromo-2’-deoxyuridine; SVZ, subventricular zone
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Lindsey, & Moore, 1980); and particularly within the SGZ (Ermine et al.,
2016) where the entirety of TH1 fibres coexpress the NA-specific
marker DBH but not the DA-specific transporter (DAT). In light of this,
we hypothesised that in a recent study reporting reduced hippocampal
neurogenesis in response to 6-OHDA lesion of midbrain DA neurons,
“off-target” depletion of the nearby locus coeruleus NA neurons may
be the relevant underlying mechanism. Surprisingly, however, we
report here that hippocampal neurogenesis was insensitive to near
complete depletion of the DA or NA projection systems, alone or in
combination, under similar experimental conditions.
FIGURE 5 Lesions of DA or NA projection systems does not affect cell proliferation in the SVZ or SGZ of adult rats 4 weeks postlesion.
Immunohistochemistry in representative coronal sections of the LC and hippocampus showed that compared with sham lesion (c, e), the i.c.
v. injection of DBH-saporin toxin robustly ablated NA neurons (c, e). TH immunoreactivity in controls (f, h) compared with the DA lesion
group, in which a near complete ablation of DA neurons in the SNpc and DA fibres occurred in the striatum after 6-OHDA administration
(g, i). Analysis of the number of Ki671 cells revealed no difference in proliferating cells in the SGZ between the NA lesion, DA lesion and
control groups (j) or in the SVZ between the DA lesion and controls (k). Statistical analysis: (j) one-way ANOVA, F2, 2050.2614, p5 .7726;
(k) unpaired t-test, p5 .6199. Error bars5 Standard deviation. Scale bars: b–i, 500 mm. Abbreviations: DBH, dopamine-b-hydroxylase; LC,
locus cœruleus; TH, tyrosine hydroxylase; SGZ, subgranular zone; SNpc, substantia nigra pars compacta; SVZ, subventricular zone [Color
figure can be viewed at wileyonlinelibrary.com]
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Perhaps more surprising was the finding that depletion of DA
innervation of the striatum and adjacent SVZ did not impair SVZ cell
proliferation either. This is again in contrast to a number of studies
with similar designs that report reductions in SVZ cell proliferation in
response to loss of DA innervation (Baker et al., 2004; H€oglinger et al.,
2004; O’Keeffe, 2009; Sui, Horne, & Stanić, 2012). We noted that in
some of these studies, cell-proliferation was assessed at shorter inter-
vals after DA lesioning than the nine-week time-point we originally
examined. Thus, to account for the possibility we had missed a
transient impact on cell-proliferation we established an additional
cohort of animals for histological assessment four weeks after lesioning
to match previous study designs. Nonetheless, the results were similar
to those observed at nine weeks, with no difference in the number of
proliferating Ki671 cells in both SGZ and SVZ despite near complete
lesioning of the DA or NA projection systems.
Comparison of other key parameters in the present experimental
design, including method of DA ablation, rodent species or strains, age,
and sex does not really identify variables that clearly account for the
descrapancy in outcome with similarly designed studies in rodents. The
study by H€oglinger et al (2004), additionally reports reduced cell prolif-
eration in SGZ and SVZ in patients with PD, relative to aged-matched
controls, and it is possible that DA differentially regulates cell prolifera-
tion across species. This is supported by findings from Baker, Baker,
and Hagg (2005) showing that activation of the D3 receptor increases
BrdU labelling of SVZ progenitors in rats but not mice.
Nonetheless, while there are a number of now well-cited studies
that conclude DA positively regulates SVZ cell proliferation, a detailed
review of the literature highlights a lack of consensus in much the
same way as has been reported for the SGZ. DA has variously been
reported to increase (Baker et al., 2004; H€oglinger et al., 2004; Van
Kampen, Hagg, Robertson, & Van Kampen, 2004; Lao, Lu, & Chen,
2013; O’Keeffe, 2009; Sui et al., 2012; Winner et al., 2006, 2009),
decrease (Aponso, Faull, & Connor, 2008; Liu et al., 2006) and have no
impact (Baker et al., 2005; van den Berge et al., 2011; Milosevic et al.,
2007) on SVZ cell proliferation (Table 1).
In this study, we were interested in basal neurogenesis to under-
stand the origin of the hippocampal neurogenesis decline observed in
PD brains (Camicioli et al., 2003; Laakso et al., 1996). However, hippo-
campal neurogenesis has been shown to be increased in an enriched
environment (Kempermann, Kuhn, & Gage, 1997) or following exercise
(van Praag, Shubert, Zhao, & Gage, 2005), and it cannot be excluded
that NA and/or DA can facilitate changes in the activity dependent reg-
ulation of hippocampal neurogenesis.
Identification of pathophysiological mechanisms underlying non-
motor symptoms in PD, including dementia, remains an important strat-
egy for the development of new therapeutic approaches. Here we
TABLE 1 Summary of studies that investigated the role of DA on SVZ proliferation and their conclusion [Color table can be viewed at
wileyonlinelibrary.com]
Study Experimental design Concluded role of DA on proliferation
Baker et al., 2004 D3 agonist, rats
Van Kampen et al., 2004 D3 agonist, rats
H€oglinger et al., 2004 MPTP, mice
Baker et al., 2005 D3 agonist, mice No effect
Liu et al., 2006 6-OHDA, rats
Winner et al., 2006 6-OHDA, rats
Milosevic et al., 2007 D2/D3 agonist, in vitro No effect
Aponso et al., 2008 6-OHDA, rats
Winner et al., 2009 DA agonist, rats
Van Den Berge et al., 2011 MPTP, mice No effect
Lao et al., 2013 D3 agonist, mice
Sui et al., 2012 6-OHDA, mice
O’Keeffe et al., 2009 6-OHDA, rats
Studies in green have reported a positive effect of DA on proliferation, studies in red have reported a negative effect and studies in white/grey have
reported no effect of DA on SVZ proliferation.
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sought to functionally link DA or NA depletion to reduced hippocampal
neurogenesis as a potential substrate for cognitive decline in PD. The
results do not support such a link and contribute to an already highly
mixed literature regarding the role of DA for regulation of cell-turnover
in the two neurogenic niches in the adult mammalian brain. Dementia
linked to neurodegeneration in PD is more likely to be directly related
to loss of DA and/or NA signalling in various target structures, while
reduced neurogenesis and hippocampal atrophy (Camicioli et al., 2003;
H€oglinger et al., 2004; Laakso et al., 1996) may well occur in parallel,
while still contributing to loss of cognitive function through independ-
ent mechanisms. Degeneration of other neurotransmitter systems may
also play a role. For example, we have recently reported that both loss
of A10 DA neurons of the VTA along with cholinergic dysfunction,
including reduced acetylcholine levels in the hippocampus, is associated
with dementia in PD (Hall et al., 2014). Studies in rodents have also
shown that impairment of certain cognitive functions are insensitive to
robust ablation of single transmitter systems but arise through simulta-
neous imbalance between multiple neurotransmitter systems (Wisman
et al., 2008). Mechanisms of neurotransmitter-based regulation of cog-
nition and hippocampal neurogenesis may well overlap under certain
conditions but the present results do not suggest a simple relationship
associated with the degeneration of the two most prominently affected
transmitter systems in PD.
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